Department of Medicine, Weill Cornell Medical Center, New York, New York, USA.
Diabetes Care. 2012 Apr;35(4):840-7. doi: 10.2337/dc11-1639. Epub 2012 Feb 14.
To investigate the association of lipoprotein-associated phospholipase A(2) (LpPLA(2)) mass and activity with incident cardiovascular disease (CVD) in a population with high prevalences of insulin resistance and diabetes, conditions for which epidemiological data remain sparse.
We conducted a nested, case-control study (n = 1,008) within a population-based cohort of American Indians. Case subjects were defined by incidence of first-ever CVD up to 10 years later. Control subjects comprised participants free of CVD events during the follow-up period who were frequency matched to case subjects by age, sex, and diabetes status. LpPLA(2) mass and activity were measured using commercially available assays.
LpPLA(2) mass and activity were moderately correlated with each other (r = 0.30), but only LpPLA(2) activity exhibited moderate correlations with lipid fractions. After extensive adjustment for covariates, both LpPLA(2) measures were significantly associated with incident CVD, but the relationship was inverse for LpPLA(2) mass (highest versus lowest tertile, relative risk [RR] 0.55 [95% CI 0.39-0.79]) and positive for LpPLA(2) activity (highest versus lowest tertile, 1.65 [1.12-2.42]). These associations were similar when participants with and without diabetes were examined separately.
In this population-based cohort enriched with dysmetabolic phenotypes, LpPLA(2) mass and activity showed divergent associations with CVD. The inverse relationship for LpPLA(2) mass is contrary to observations from predominantly nondiabetic populations and will require independent replication. Whether this finding relates to redistribution of LpPLA(2) to lipoprotein classes where it is less atherogenic or reflects incomplete measurement of LpPLA(2) mass associated with altered lipoprotein composition in insulin resistance warrants further investigation.
在一个胰岛素抵抗和糖尿病患病率较高的人群中,研究脂蛋白相关磷脂酶 A2(LpPLA2)质量和活性与心血管疾病(CVD)事件的相关性。该人群中,关于脂蛋白相关磷脂酶 A2 的流行病学数据仍然较少。
我们对一个基于人群的美国印第安人群体进行了嵌套病例对照研究(n=1008)。病例组的定义为 10 年内首次发生 CVD。对照组为在随访期间无 CVD 事件的参与者,按年龄、性别和糖尿病状态与病例组进行频数匹配。采用商业上可获得的检测方法测量 LpPLA2 质量和活性。
LpPLA2 质量和活性中度相关(r=0.30),但只有 LpPLA2 活性与脂质分数中度相关。经过大量协变量调整后,两种 LpPLA2 测量值均与 CVD 事件显著相关,但 LpPLA2 质量呈负相关(最高与最低三分位,相对风险 [RR]0.55[95%CI0.39-0.79]),LpPLA2 活性呈正相关(最高与最低三分位,1.65[1.12-2.42])。在分别检查有和无糖尿病的参与者时,这些关联是相似的。
在这个以代谢异常表型为特征的基于人群的队列中,LpPLA2 质量和活性与 CVD 有不同的关联。LpPLA2 质量的负相关与主要来自非糖尿病人群的观察结果相反,需要独立复制。这种发现是否与 LpPLA2 向脂蛋白类别的重新分布有关,在这些脂蛋白类中,LpPLA2 的致动脉粥样硬化性降低,或者反映了胰岛素抵抗中脂蛋白组成改变相关的 LpPLA2 质量的不完全测量,这值得进一步研究。